PVLAPalvella Therapeutics Inc
$110.00
$6.39
(5.49%)
Closed $110.12
$0.12
(0.11%)
After Hours
EarningsAug 13
Mkt Cap$1.67B
Vol251,736.00
Fundamentals
50
Neutral Sentiment
How do you feel about PVLA?
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors PR Newswire BERKELEY, Calif., June 9, 2026 BERKELEY, Calif., June 9, 2026 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering a topical cell...
PR Newswire
Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA
Jennison Associates LLC boosted its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 262.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,483 shares of the company's stock after purchasing an additional...
MarketBeat
Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday
Palvella Therapeutics (NASDAQ:PVLA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-palvella-therapeutics-stock...
MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the stock, Marketbeat reports...
MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - What's Next?
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - Time to Buy...
MarketBeat
Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA
Deltec Asset Management LLC decreased its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 80.8% in the 4th quarter, according to the company in its most recent filing with the...
MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Downgraded by Wall Street Zen to "Sell"
Wall Street Zen downgraded Palvella Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are covering the company, MarketBeat.com...
MarketBeat
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Investment analysts at Lifesci Capital lowered their FY2026 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to...
MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for PVLA
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 EPS estimates for shares of Palvella Therapeutics in a research note issued...
MarketBeat
<
1
2
...
>